The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Main Article Content

Amy Paller
Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago IL, USA

Jonathan Silverberg
Department of Dermatology, George Washington University, Washington DC, USA

H. Chih ho Hong
Department of Dermatology and Skin Science, University of British Columbia and Probity Medical Research, Surrey, BC, Canada

Michael Cork
Sheffield Dermatology Research, Department of Infection, Immunity, and Cardiovascular Disease, The University of Sheffield and Sheffiel d T eaching Hospitals, NIHR Clinical Research Facility, Sheffield, UK

Luis Puig
Department of Dermatology, Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona, Barcelona, Spain

Petra Arlert
LEO Pharma A/S, Ballerup, Denmark

Azra Kurbasic
LEO Pharma A/S, Ballerup, Denmark

Lise Soldbro
LEO Pharma A/S, Ballerup, Denmark

Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Keywords

atopic dermatitis, tralokinumab

References

1. Bieber T. Allergy. 2020;75:54 62.

2. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480 89.

3. Popovic B, et al. J Mol Biol. 2017;429:208 19.

4. Ng M, et al. Australas J Dermatol. 2018;59:e114 e17.

5. Ghio D, et al. Br J Health Psychol . 2021;26:214 31.

6. Manjunath J, et al. J Eur Acad Dermatol Venereol . 2022;36:e346 e48.

7. Wollenberg A, et al. Presented at European Society for Pediatric Dermatology 21st Annual Meeting 2022.

8. Paller A , et al . Presented at 2021 Fall Clinical Dermatology Conference 40th Annual

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.139

Article Details

How to Cite
[1]
Paller, A., Silverberg, J., Hong, H.C. ho, Cork, M., Puig, L., Arlert, P., Kurbasic, A., Soldbro, L. and Simpson, E. 2023. The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s139. DOI:https://doi.org/10.25251/skin.7.supp.139.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>